Oral Anlotinib Maintenance Therapy for an Advanced Malignant Peritoneal Mesothelioma Diagnosed by Laparoscopy After Initial Misdiagnosis to Obtain Longer Progression-Free Survival: Case Report and Literature Review

References

• Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. 2021;47(1):36–59. PMID: 32209311. doi:10.1016/j.ejso.2020.02.011
   PubMed Web of Science ®Google Scholar
• Zhao J, Zuo TT, Zheng RS, et al. Epidemiology and trend analysis on malignant mesothelioma in China. Chin J Cancer Res. 2017;29(4):361–368. PMID: 28947868. doi:10.21147/j.issn.1000-9604.2017.04.09
   PubMed Web of Science ®Google Scholar
• Manzini VDP, Recchia L, Cafferata M, et al. Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol. 2010;21(2):348–353. PMID: 19635740. doi:10.1093/annonc/mdp307
   PubMed Web of Science ®Google Scholar
• Grzankowski KS, Brightwell RM, Kasznica JM, et al. Malignant peritoneal mesothelioma without asbestos exposure: an ovarian cancer imitator. Gynecol Oncol Rep. 2014;17(11):10–12. PMID: 26076085. doi:10.1016/j.gore.2014.11.002
   Google Scholar
• Boussios S, Moschetta M, Karathanasi A, et al. Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives. Ann Gastroenterol. 2018;31(6):659–669. PMID: 30386115. doi:10.20524/aog.2018.0305
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018;142(1):89–108. PMID: 28686500. doi:10.5858/arpa.2017-0124-RA
   PubMed Web of Science ®Google Scholar
• Gudmundsson E, Labby Z, Straus CM, et al. Dynamic contrast - enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. Eur Radiol. 2019;29(2):682–688. PMID: 29967955. doi:10.1007/s00330-018-5533-9
   PubMed Web of Science ®Google Scholar
• Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta ⁃ analysis. Ann Surg Oncol. 2015;22(5):1686⁃1693. PMID: 25124472. doi:10.1245/s10434-014-3978-x
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Cabras AD, et al. Diffuse malig⁃ nant peritoneal mesothelioma: long⁃term survival with complete cy⁃ toreductive surgery followed by hyperthermic intraperitoneal chemo⁃ therapy (HIPEC. Eur J Cancer. 2013;49(15):3140–3148. PMID: 23831335. doi:10.1016/j.ejca.2013.05.027
   PubMed Web of Science ®Google Scholar
• García-Fadrique A, Mehta A, Mohamed F, et al. Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review. J Gastrointest Oncol. 2017;8(5):915–924. PMID: 29184697. doi:10.21037/jgo.2017.08.01
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Update on the management of malignant peritoneal mesothelioma. Transl Lung Cancer Res. 2018;7(5):599–608. PMID: 30450299. doi:10.21037/tlcr.2018.08.03
   PubMed Web of Science ®Google Scholar
• Alexander HR, Li CY, Kennedy TJ. Current management and future opportunities for peritoneal metastases: peritoneal mesothelioma. Ann Surg Oncol. 2018;25(8):2159–2164. PMID: 29423664. doi:10.1245/s10434-018-6337-5
   PubMed Web of Science ®Google Scholar
• Kim J, Bhagwandin S, Labow DM, et al. Malignant peritoneal mesothelioma: a review. Ann Transl Med. 2017;5(11):236. PMID: 28706904. doi:10.21037/atm.2017.03.96
   PubMed Web of Science ®Google Scholar
• Fujimoto E, Kijima T, Kuribayash K, et al. First ⁃line che⁃ motherapy with pemetrexed plus cisplatin for malignant peritoneal mesothelioma. Expert Rev Anticancer Ther. 2017;17(9):865–872. PMID: 28594258. doi:10.1080/14737140.2017.1340157
   PubMed Web of Science ®Google Scholar
• Nagata Y, Sawada R, Takashima A, et al. Efficacy and safety of pemetrexed plus cisplatin as first⁃line chemotherapy in advanced malignant peritoneal mesothelioma.Jpn. J Clin Oncol. 2019;49(11):1004–1008. PMID: 31287877. doi:10.1093/jjco/hyz104
   Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma avastin cisplatin pemetrexed study (MAPS): a randomised, controlled, open⁃label, Phase 3 trial. Lancet. 2016;387(10026):1405–1414. PMID: 26719230. doi:10.1016/S0140-6736(15)01238-6
   PubMed Web of Science ®Google Scholar
• Alley W, Lopez J, Santoro A, et al. Clinical safety and ac⁃ tivity of pembrolizumab in patients with malignant pleural mesothe⁃ lioma (KEYNOTE ⁃ 028): preliminary results from a non ⁃ ran⁃ domised, open⁃label, phase 1b trial. Lancet Oncol. 2017;18(5):623–630. PMID: 28291584. doi:10.1016/S1470-2045(17)30169-9
   PubMed Web of Science ®Google Scholar
• Bridda A, Padoan I, Mencarelli R, et al. Peritoneal mesothelioma: a review. Med Gen Med. 2007;9(2):32. PMID: 17955087 PMCID: PMC1994863.
   PubMedGoogle Scholar
• Sheaff M. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: complementary statement from the international mesothelioma interest group, also endorsed by the international academy of cytology and the papanicolaou society of cytopathology. A proposal to be applauded and promoted but which requires updating. Diagn Cytopathol. 2020;48(10):877–879. PMID: 31976625. doi:10.1002/dc.24318
   PubMed Web of Science ®Google Scholar
• Arif Q, Husain AN. Malignant mesothelioma diagnosis. Arch Pathol Lab Med. 2015;139(8):978–980. PMID: 26230591. doi:10.5858/arpa.2013-0381-RA
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636‐2644. doi:10.1200/JCO.2003.11.136
   Web of Science ®Google Scholar
• Shukuya T, Takahashi T, Imai H, et al. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients. Respir Investig. 2014;52(2):101–106. PMID: 24636265. doi:10.1016/j.resinv.2013.07.002
   PubMedGoogle Scholar
• Dudek AZ, Wang X, Gu L, et al. Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901. Clin Lung Cancer. 2020;21:553–561e1. PMID: 32727707. doi:10.1016/j.cllc.2020.06.025
   PubMed Web of Science ®Google Scholar
• Scherpereel A, Wallyn F, Albelda SM, et al. Novel therapies for malignant pleural mesothelioma. Lancet Oncol. 2018;19(3):e161–e172. PMID: 29508763. doi:10.1016/S1470-2045(18)30100-1
   PubMed Web of Science ®Google Scholar
• Hotta K, Fujimoto N. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma. J Immunother Cancer. 2020;8(1):e000461. PMID: 32098830. doi:10.1136/jitc-2019-000461
   PubMed Web of Science ®Google Scholar
• Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022;33(5):488–499. PMID: 35124183. doi:10.1016/j.annonc.2022.01.074
   PubMed Web of Science ®Google Scholar
• Calabrò L, Morra A, Giannarelli D, et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, Phase 2 study. Lancet Respir Med. 2018;6(6):451–460. PMID: 29773326. doi:10.1016/S2213-2600(18)30151-6
   PubMed Web of Science ®Google Scholar
• Chia PL, Scott AM, John T. Epidermal growth factor receptor (EGFR) ⁃targeted therapies in mesothelioma. Expert Opin Drug Deliv. 2019;16(4)::441⁃451. PMID: 30916586. doi:10.1080/17425247.2019.1598374
   PubMed Web of Science ®Google Scholar
• Hung YP, Dong F, Watkins JC, et al. Identification of ALK rearrangements in malignant peritoneal mesothelioma. JAMA Oncol. 2018;4(2)::235⁃238. PMID: 28910456. doi:10.1001/jamaoncol.2017.2918
   Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039–2049. doi:10.1056/NEJMra0706596
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20(21):4368–4380. doi:10.1200/JCO.2002.10.088
   PubMed Web of Science ®Google Scholar
• Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001;193(4):468–475. PMID: 11276005. doi:10.1002/path.824
   PubMed Web of Science ®Google Scholar
• Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021;22(10):1438–1447. PMID: 34499874. doi:10.1016/S1470-2045(21)00404-6
   PubMed Web of Science ®Google Scholar
• Grosso F, Steele N, Novello S, et al. Nintedanib plus pemetrexed/ cisplatin in patients with malignant pleural mesothelioma: phase ii results from the randomized, placebo-controlled LUMEMeso trial. J Clin Oncol. 2017;35(31):3591–3600. PMID: 28892431. doi:10.1200/JCO.2017.72.9012
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Gaafar R, Nowak AK, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy‐naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569–580. PMID: 31103412. doi:10.1016/S2213-2600(19)30139-0
   PubMed Web of Science ®Google Scholar
• Yang ZR, Chen ZG, Du XM, et al. Apatinib mesylate inhibits the proliferation and metastasis of epithelioid malignant peritoneal mesothelioma in vitro and in vivo. Front Oncol. 2020;10:585079. PMID: 33365269 PMCID: PMC7750508. doi:10.3389/fonc.2020.585079
   PubMed Web of Science ®Google Scholar
• Lin B, Song X, Yang D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 2018;654(654):77–86. PMID: 29454091. doi:10.1016/j.gene.2018.02.026
   PubMedGoogle Scholar
• Xie C, Wan X, Quan H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor. Cancer Sci. 2018;109(4):1207–1219. PMID: 29446853 PMCID: PMC5891194. doi:10.1111/cas.13536
   PubMed Web of Science ®Google Scholar
• Chen XZ. Anlotinib for refractory advanced non‐small cell lung cancer in China. JAMA Oncol. 2019;5(1):116‐117. PMID: 30489609. doi:10.1001/jamaoncol.2018.5526
   Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9:105. doi:10.1186/s13045-016-0332-8
   PubMed Web of Science ®Google Scholar
• Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018;11(1):120. PMID: 30231931 PMCID: PMC6146601. doi:10.1186/s13045-018-0664-7
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft‐tissue sarcoma. Clin Cancer Res. 2018;24(21):5233‐5238. PMID: 29895706. doi:10.1158/1078-0432.CCR-17-3766
   Web of Science ®Google Scholar
• Yao W, Du X, Wang J, Wang X, Zhang P, Niu X. Long-term efficacy and safety of anlotinib as a monotherapy and combined therapy for advanced sarcoma. Onco Targets Ther. 2022;15:669–679. doi:10.2147/OTT.S365506
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Martinetti A, et al. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol. 2007;14(2):500–508. PMID: 17151789. doi:10.1245/s10434-006-9192-8
   PubMed Web of Science ®Google Scholar